A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances.
- Authors
- Peñas-Lledó, E; Guillaume, S; Naranjo, M E G; Delgado, A; Jaussent, I; Blasco-Fontecilla, H; Courtet, P; LLerena, A
- Year
- 2015
- Journal
- The pharmacogenomics journal
- PMID
- 25113522
- DOI
- 10.1038/tpj.2014.42
This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combination increases the likelihood of suicidal intent severity in a large study cohort. Survivors of a suicide attempt (n=587; 86.8% women) were genotyped for CYP2C19 (*2, *17) and CYP2D6 (*3, *4, *4xN, *5, *6, *10, wtxN) genetic variation and evaluated with the Beck Suicide Intent Scale (SIS). Patients with a high CYP2D6-CYP2C19 metabolic capacity showed an increased risk for a severe suicide attempt (P<0.01) as measured by the SIS-objective circumstance subscale (odds ratio (OR)=1.37; 95% confidence interval (CI)=1.05-1.78; P=0.02) after adjusting for confounders (gender, age, level of studies, marital status, mental disorders, tobacco use, family history of suicide, personal history of attempts and violence of the attempt). Importantly, the risk was greater in those without a family history of suicide (OR=1.82; CI=1.19-2.77; P=0.002). Further research is warranted to evaluate whether the observed relationship is mediated by the role of CYP2D6 and CYP2C19 involvement in the endogenous physiology or drug metabolism or both.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. | 2018 | 28373689 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Characterization of trazodone metabolic pathways and species-specific profiles. | Petrucci V et al. | — | 2025 | → |
| CYP2D6 and CYP2C19 ultrarapid metabolisms are associated with suicide attempts in schizophrenia. | Korchia T et al. | — | 2025 | → |
| <i>CYP2C19</i> genotype-phenotype correlation: current insights and unanswered questions. | Torso NG et al. | — | 2024 | → |
| Cytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa. | Radhakrishna U et al. | — | 2023 | → |
| Outpatient Pharmacogenomic Screenings to Prevent Addiction, Overdose, and Suicide. | Yarlagadda A et al. | — | 2023 | → |
| A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts. | Peñas-Lledó EM et al. | — | 2022 | → |
| Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances. | Sheng Y et al. | — | 2021 | → |
| A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. | Kanders SH et al. | — | 2020 | → |
| Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans. | Rodrigues-Soares F et al. | — | 2020 | → |
| Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. | Culverhouse RC et al. | — | 2018 | → |
| Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. | Naranjo MG et al. | — | 2018 | → |
| The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. | Haduch A et al. | — | 2018 | → |
| CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine? | de Andrés F et al. | — | 2017 | → |
| High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. | Moya G et al. | — | 2017 | → |
| Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. | Takahashi PY et al. | — | 2017 | → |
| Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk. | Yarlagadda A et al. | — | 2017 | → |
| CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients. | Stephens DB et al. | — | 2016 | → |
| High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies. | Naranjo ME et al. | — | 2016 | → |
| Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. | Fricke-Galindo I et al. | — | 2016 | → |
| Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach. | de Andrés F et al. | — | 2016 | → |
| Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). | Sosa-Macias M et al. | — | 2015 | → |